TTM
$10.9B
YoY change
-2.8%
5Y CAGR
+2.6%
Peak year (FY2021)
$12B
Cumulative EBITDA
$124B
EBITDA history chart for Thermo Fisher Scientific (TMO) from 2016 to 2025
Latest: $11.5B
EBITDA growth chart for Thermo Fisher Scientific (TMO) from 2016 to 2025
Latest: -2.8%
EBITDA history table for Thermo Fisher Scientific (TMO) from 1985 to 2025
| FY2025 | $11.5B | -2.8% | -$334M | ||
| FY2024 | $11.8B | +5.4% | +$605M | ||
| FY2023 | $11.2B | -6.3% | -$747M | ||
| FY2022 | $11.9B | -0.2% | -$27M | ||
| FY2021 | $12B | +18.4% | +$1.86B | ||
| FY2020 | $10.1B | +43.9% | +$3.09B | ||
| FY2019 | $7.02B | +13.4% | +$828M | ||
| FY2018 | $6.2B | +22.6% | +$1.14B | ||
| FY2017 | $5.05B | +18.9% | +$803M | ||
| FY2016 | $4.25B | +5.2% | +$212M | ||
| FY2015 | $4.04B | -5.0% | -$212M | ||
| FY2014 | $4.25B | +64.7% | +$1.67B | ||
| FY2013 | $2.58B | +3.5% | +$87M | ||
| FY2012 | $2.49B | +14.2% | +$311M | ||
| FY2011 | $2.18B | +14.2% | +$272M | ||
| FY2010 | $1.91B | +4.3% | +$79.6M | ||
| FY2009 | $1.83B | -11.6% | -$240M | ||
| FY2008 | $2.07B | +16.6% | +$294M | ||
| FY2007 | $1.78B | +254.1% | +$1.28B | ||
| FY2006 | $502M | +15.2% | +$66.2M | ||
| FY2005 | $436M | +29.6% | +$99.5M | ||
| FY2004 | $336M | +20.4% | +$57M | ||
| FY2003 | $279M | +44.7% | +$86.2M | ||
| FY2002 | $193M | -27.3% | -$72.3M | ||
| FY2001 | $265M | -10.2% | -$30.2M | ||
| FY2000 | $296M | -18.4% | -$66.6M | ||
| FY1999 | $362M | +2.5% | +$8.8M | ||
| FY1998 | $353M | -4.9% | -$18.2M | ||
| FY1997 | $372M | -7.0% | -$27.8M | ||
| FY1996 | $399M | +20.2% | +$67.1M | ||
| FY1995 | $332M | +37.3% | +$90.2M | ||
| FY1994 | $242M | +45.8% | +$76.1M | ||
| FY1993 | $166M | +70.3% | +$68.5M | ||
| FY1992 | $97.5M | +58.0% | +$35.8M | ||
| FY1991 | $61.7M | +13.4% | +$7.3M | ||
| FY1990 | $54.4M | +78.4% | +$23.9M | ||
| FY1989 | $30.5M | +0.7% | +$200K | ||
| FY1988 | $30.3M | +72.2% | +$12.7M | ||
| FY1987 | $17.6M | -15.0% | -$3.1M | ||
| FY1986 | $20.7M | +63.0% | +$8M | ||
| FY1985 | $12.7M | — | — |
- FY2025$11.5B-2.8%
- FY2024$11.8B+5.4%
- FY2023$11.2B-6.3%
- FY2022$11.9B-0.2%
- FY2021$12B+18.4%
- FY2020$10.1B+43.9%
- FY2019$7.02B+13.4%
- FY2018$6.2B+22.6%
- FY2017$5.05B+18.9%
- FY2016$4.25B+5.2%
- FY2015$4.04B-5.0%
- FY2014$4.25B+64.7%
- FY2013$2.58B+3.5%
- FY2012$2.49B+14.2%
- FY2011$2.18B+14.2%
- FY2010$1.91B+4.3%
- FY2009$1.83B-11.6%
- FY2008$2.07B+16.6%
- FY2007$1.78B+254.1%
- FY2006$502M+15.2%
- FY2005$436M+29.6%
- FY2004$336M+20.4%
- FY2003$279M+44.7%
- FY2002$193M-27.3%
- FY2001$265M-10.2%
- FY2000$296M-18.4%
- FY1999$362M+2.5%
- FY1998$353M-4.9%
- FY1997$372M-7.0%
- FY1996$399M+20.2%
- FY1995$332M+37.3%
- FY1994$242M+45.8%
- FY1993$166M+70.3%
- FY1992$97.5M+58.0%
- FY1991$61.7M+13.4%
- FY1990$54.4M+78.4%
- FY1989$30.5M+0.7%
- FY1988$30.3M+72.2%
- FY1987$17.6M-15.0%
- FY1986$20.7M+63.0%
- FY1985$12.7M—
EBITDA values are taken from Thermo Fisher Scientific's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Thermo Fisher Scientific (TMO)
According to Thermo Fisher Scientific's latest reported financial statements, the company's current EBITDA (TTM) is $10.9B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Thermo Fisher Scientific (TMO) EBITDA is $11.5B – edged down 2.8% year-over-year.
Thermo Fisher Scientific EBITDA has grown on net over the period, with a +2.6% compound annual growth rate over 2020–2025 (5 years).
Between 2021 and 2025, Thermo Fisher Scientific EBITDA edged down 4.2%, falling from $12B to $11.5B.
2021 marks the peak EBITDA at $12B, with the historical low of $12.7M recorded in 1985.
Thermo Fisher Scientific EBITDA by Year
Thermo Fisher Scientific EBITDA 2025: $11.5B
In 2025, Thermo Fisher Scientific reported EBITDA of $11.5B, edged down 2.8% below 2024.
Thermo Fisher Scientific EBITDA 2024: $11.8B
Thermo Fisher Scientific EBITDA in 2024 was $11.8B, grew 5.4% from 2023.
Thermo Fisher Scientific EBITDA 2023: $11.2B
2023's EBITDA for Thermo Fisher Scientific came in at $11.2B, declined 6.3% below 2022.
Thermo Fisher Scientific EBITDA 2022: $11.9B
Thermo Fisher Scientific posted EBITDA of $11.9B in 2022, edged down 0.2% below 2021.
Thermo Fisher Scientific EBITDA 2021: $12B
Thermo Fisher Scientific EBITDA in 2021 was $12B.
See more financial history for Thermo Fisher Scientific (TMO).
Sector peers by EBITDA
Healthcare peers of Thermo Fisher Scientific (TMO), ranked by their latest EBITDA
| $41.1B | |
| $28.3B | |
| $27.9B | |
| $24.4B | |
| $23.1B | |
| $17.6B | |
| $16.9B | |
| $11.6B |
- $41.1B
- $28.3B
- $27.9B
- $24.4B
- $23.1B
- $17.6B
- $16.9B
Frequently asked questions
Thermo Fisher Scientific (TMO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks4.73% TTM
- Dividend Profile0.31% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History8 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.